Cell Impact AB reported its financial results for the fourth quarter (Q4) of 2025. Net sales for the period totaled SEK 1.1 million. The operating loss $(EBIT)$ amounted to SEK -65.4 million, while the loss after financial items was SEK -66.4 million. Earnings per share before and after dilution were SEK -0.23. The Group’s debt/equity ratio stood at 74 percent at the end of the quarter. Cash flows from operating activities were SEK -3.1 million, with cash and cash equivalents at the balance sheet date amounting to SEK 10.9 million. As of February 3, 2026, cash and cash equivalents were SEK 4.9 million. On the business front, Cell Impact AB intensified efforts to lay the foundation for future volume orders and moved into an initial phase of continuous production with a key customer, expecting a gradual increase in flow plate deliveries. The company also announced a strategic cooperation agreement with thyssenkrupp Automation Engineering and signed a new agreement with a leading Asian vehicle manufacturer for the delivery of a forming tool. To support ongoing activities and future growth, Cell Impact AB will soon begin a guaranteed rights issue, expected to provide up to SEK 33.2 million after issue costs, as the company continues its diversification and commercialization strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cell Impact AB published the original content used to generate this news brief via Cision (Ref. ID: 20260203:BIT:5609:0) on February 04, 2026, and is solely responsible for the information contained therein.